Welcome to BioSeeker Group!

Biologicals in Oncology Drug Pipeline Update

Additional Information

Published Date Aug 4, 2016
Format Desktop App plus Online Access to Updates (One Year)
Publisher BioSeeker Group
Product Line View All Available Drug Pipeline Update Reports

Availability: In stock

$3,675.00

Quick Overview

BioSeeker Group have identified 1371 companies plus partners who are today developing 2823 biological drugs in 6088 developmental projects in cancer across 801 different targets. In addition, there are 25 suspended drugs and another 1050 drugs where development has been ceased.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Biologicals in Oncology Drug Pipeline Update.

    To find out more about Biologicals in Oncology Drug Pipeline Update, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Biologicals in Oncology Drug Pipeline Update is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or
Extra value: One year of free online updates included with this product

Executive Summary

BioSeeker Group have identified 1371 companies plus partners who are today developing 2823 biological drugs in 6088 developmental projects in cancer across 801 different targets. In addition, there are 25 suspended drugs and another 1050 drugs where development has been ceased.

For busy executives within Pharma, Biotech and Investment companies who know they need to stay on top of the developmental environment in their field, we offer the Drug Pipeline update series.

You get detailed, world-wide drug pipeline information, delivered in an unbiased and independent pipeline progress analysis for each identified drug.

Buying the Biologicals in Oncology Drug Pipeline Update will mean you have this important data at your fingertips and ensure that you can:

* Show investors/board/management that you are right on top of drug development progress in your therapeutic area.
* Find competitors, collaborations partners, M&A candidates etc. and track them by their products.
* Jump start competitive drug intelligence operations
* Benchmark your own development against world wide data
* Compare portfolio and therapy focus with your peers
* Speed up pro-active in-/outlicensing strategy work

Our software lets you define your selectivity in each drug search with up to 24 different drug specific parameters. Each parameter has multi-select options to them and can be used as either an inclusion parameter or exclusion parameter.


The following short video playlist demonstrates the use of the filter sections, how you can make an inclusion and exclusion search and what to expect from a drug profile result.


Some facts about Biologicals in Oncology Drug Pipeline Update

This drug pipeline update covers a wide array of biological drugs, such as: antibodies,proteins, peptides, DNA, RNA and cellular therapies.
There are today 1371 companies plus partners developing 2823 biological drugs in 6088 developmental projects in cancer. In addition, there are 25 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 1050 drugs. Biologicals In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 801 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 715 out of the 722 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 89 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.


Details from Biologicals in Oncology Drug Pipeline Update at a glance

This short overview shows actual findings from the Biologicals in Oncology Drug Pipeline Update report.

Companies Includes more than 1371 principal companies plus their collaborators. There is direct access from inside the application to web pages of all principal companies.

Note: You are able to sort and find drugs according to companies and partners from drop-down menus in the application. You may also sort and find drugs according to country of companies.
Drug name & Synonyms Lists commercial, generic and code names for drugs.
Developmental stage This Drug Pipeline Update contains 2823 biological drugs in development, which have a total of 6088 developmental projects in cancer. In addition there are suspended and ceased drugs.

Pipeline Breakdown According to Number of Drugs
Marketed# 197
Registered# 1
Pre-registration# 14
Phase III# 167
Phase II# 532
Phase I# 657
Preclinical# 1435
No Data# 49
Suspended# 25
Ceased# 1050

Note: You are able to sort and find drugs according to developmental stage from drop-down menu in the application.
Indications Included biological drugs are also in development for 477 other indications, where of 202 are different cancer indications.

Note: You are able to find and sort drugs according to type of indication from drop-down menu in the application.
Targets Mutations
All targets are cross-referenced with the Catalogue of Somatic Mutations in Cancer (COSMIC). It is designed to store and display somatic mutation information and related details and contains information relating to human cancers. To date 715 out of the 722 studied drug targets so far have been recorded with somatic mutations and the software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information.

Biological Structures
The identity of available biological structures on 467 drug targets was retrieved from the RCSB Protein Databank for you to easily review the 5898 structures available today among drug targets.

Identified drugs are linked to more than 801 different targets, divided into 89 classifications of molecular function:
- Acid phosphatase activity
- Antigen binding
- ATPase activity
- Auxiliary transport protein activity
- B cell receptor activity
- Binding
- Calcium ion binding
- Carboxy-lyase activity
- Carboxypeptidase activity
- Catalytic activity
- Cell adhesion molecule activity
- Chaperone activity
- Chemokine activity
- Cofactor binding
- Complement activity
- Cysteine-type peptidase activity
- Cytokine activity
-
- Cytoskeletal anchoring activity
- Cytoskeletal protein binding
- Deacetylase activity
- Deaminase activity
- Defense/immunity protein activity
- DNA binding
- DNA repair protein
- DNA topoisomerase activity
- DNA-directed DNA polymerase activity
- DNA-directed RNA polymerase activity
- DNA-methyltransferase activity
- Extracellular ligand-gated ion channel activity
- Extracellular matrix structural constituent
- G-protein coupled receptor activity
- Growth factor activity
- Growth factor binding
- GTPase activator activity
- GTPase activity
- Guanylate cyclase activity
- Heat shock protein activity
- Helicase activity
- Hormone activity
- Hydrolase activity
- Intracellular ligand-gated ion channel activity
- Isomerase activity
- Kinase activity
- Kinase binding
- Kinase regulator activity
- Ligand-dependent nuclear receptor activity
- Ligase activity
- Lipid kinase activity
- Lipid phosphatase activity
- Metallopeptidase activity
- MHC class I receptor activity
- Molecular function unknown
- Motor activity
- Oxidoreductase activity
- Peptidase activity
- Peptide hormone
- Peroxidase activity
- Phosphoric diester hydrolase activity
- Protease inhibitor activity
- Protein binding
- Protein serine/threonine kinase activity
- Protein threonine/tyrosine kinase activity
- Protein tyrosine phosphatase activity
- Protein tyrosine/serine/threonine phosphatase activity
- Protein-tyrosine kinase activity
- Receptor activity
- Receptor binding
- Receptor signaling complex scaffold activity
- Receptor signaling protein serine/threonine kinase activity
- Receptor signaling protein tyrosine phosphatase activity
- RNA binding
- RNA-directed DNA polymerase activity
- Serine-type peptidase activity
- Signal transducer activity
- Structural constituent of cytoskeleton
- Structural molecule activity
- Superoxide dismutase activity
- T cell receptor activity
- T cell receptor binding
- Transcription factor activity
- Transcription regulator activity
- Transferase activity
- Translation regulator activity
- Transmembrane receptor activity
- Transmembrane receptor protein tyrosine kinase activity
- Transporter activity
- Ubiquitin-specific protease activity
- Unclassified
- Voltage-gated ion channel activity

Sub-Cellular Localization
Identified targets are categorized into 42 different primary and alternate sub-cellular localizations:
- Apical membrane
- Basolateral membrane
- Cell junction
- Cell surface
- Centrosome
- Chromosome
- Clathrin-coated vesicle
- Cytoplasm
- Cytoplasmic vesicle
- Cytoskeleton
- Cytosol
- Early endosome
- Endoplasmic reticulum
- Endosome
- Extracellular
- Extracellular matrix
- Golgi apparatus
- Golgi membrane
- Immunological synapse
- Integral to membrane
- Intermediate filament
- Kinetochore
- Late endosome
- Lysosome
- Membrane fraction
- Microtubule
- Mitochondrial matrix
- Mitochondrial membrane
- Mitochondrion
- Nucleolus
- Nucleus
- Perinuclear region
- Perinuclear vesicle
- Peroxisomal matrix
- Plasma membrane
- Sarcoplasmic reticulum
- Secreted
- Secretory granule
- Secretory vesicle
- Soluble fraction
- Vesicle
- Zymogen granule

Note: You are able to find and sort drugs according to target gene name, protein name, molecular function of target, target localization, presence of mutations and availability of biological structures of target from drop-down menus in the application.
Target Expression Profile Direct links are provided from inside the application to 986 protein expression profiles of 643 drug targets in various human tissues and cancer types, cell lines and primary cells, including up to:
- 48 different normal tissue types
- 20 different types of cancer
- 47 cell lines
- 12 samples of primary blood cells
Pathway Referals Identified targets have been cross referenced against their involvement in different cellular pathways, according to BioCarta, KEGG, NCI-Nature and NetPath.
- BioCarta# 269 Pathways
- KEGG# 214 Pathways
- NCI-Nature# 251 Pathways
- NetPath# 32 Pathways

Note: You are able to find and sort drugs according to targeted pathways from drop-down menus in the application.
Mechanism In total there are different drug mechanism of action represented in this Drug Pipeline Update.

Note: You are able to find and sort drugs according to mechanism of action from drop-down menu in the application.
Compound Identified drug compounds are described by:

Compound type, Chemical name, CAS Number and molecular weight

Note: You are able to sort and find drugs according to compound type from drop-down menu in the application.


The Drug Profiles: Progress analysis and review of drug development.

Biologicals in Oncology Drug Pipeline Update provides you with a profile for each identified drug.
Click here for a short video (6m 12s) showing a typical drug profile

A typical drug profile reports on, depending on stage of development and available information:

Drug Name & SynonymsPresentation of drug name and synonyms.
Principal Company & Partners Presentation of principal Company and partners.
Target and Molecular Function of Target Described target(s) is/are presented with: Official Gene Symbol – Chromosome Location – Gene & Protein Name – Molecular Function
Target Localization Described target(s) is/are presented with primary and alternate localizations.
Target Expression Profiles
Links to protein expression profile(s) of target(s) in various human tissues, cell lines and primary cells, including up to:
48 different normal tissue types
20 different types of cancer
47 cell lines
12 samples of primary blood cells
Mutation All targets are cross-referenced with the Catalogue of Somatic Mutations in Cancer (COSMIC). It is designed to store and display somatic mutation information and related details and contains information relating to human cancers.
Biological Structures The identity of available biological structures on drug targets was retrieved from the RCSB Protein Databank for you to easily review what available structures of drug targets exist.
Targeted Pathways Described target(s) is/are matched for the involvement in cellular pathways according to BioCarta, KEGG, NCI-Nature and NetPath.
Mechanism Drug mechanism of action
Developmental Projects Summary field of developmental projects for the drug, including indication, developmental stage and status.
Example:
Cancer, myeloma – Phase II Clinical Trial – Active
Cancer, prostate – Phase III Clinical Trial – Ceased
Drug Description Short introduction to drug
Compound Data Compound type, Chemical name, CAS Number and molecular weight.
Patent Data Available patent information related to the drug is presented here.
Fillings and Approvals Approvals and submissions
Analyst comments
Deals and Licensing Collaborations and deals
Availability for licensing
Phase IV Data Available Phase IV development data, developmental history and scientific data.
Phase III Data Available Phase III development data, developmental history and scientific data.
Phase II Data Available Phase II development data, developmental history and scientific data.
Phase I Data Available Phase I development data, developmental history and scientific data.
Phase 0 Data Available Phase 0 development data, developmental history and scientific data.
Preclinical Data Available Preclinical data, developmental history and scientific data.
Discovery Data Available discovery development data, developmental history and scientific data., developmental history and scientific data.


About the unique Drug Pipeline Update Software Application

After purchase, the Drug Pipeline Update is delivered to you via electronic download in a powerful yet easy to use desktop application which requires no installation.

Find and sort drugs by twenty-four different parameters, all of which can be used as inclusion or exclusion parameters, plus free text search field. Our dynamic report generator lets you easily and quickly generate HTML drug profile reports directly in your web browser, whether it is a single drug profile or your own report of a selection of drugs that match your criteria.


Application Features Search, Find and Filter Panel with Initial Result Presentation
With this panel you can define your selectivity in each drug search with up to 24 different drug specific parameters. Each parameter has multi-select options to them and can be used as either an inclusion parameter or exclusion parameter.
Click here for a short video (2m 14s) showing an overview of the filters.

The initial result table is a dynamic sortable table which gives you a fast overview of found results and can be narrowed down further by your own additional keywords.
Click here for a short video (3m 26s) showing an example of an inclusion and exclusion search to create the initial results table.

Direct linkage from inside the application to related internet resources
- Drug data is linked to search engines like Google and PubMed
- Drug target data is linked directly to BioCarta, Human Protein Atlas, KEGG, NCI-Nature, NetPath etc.
- Direct links to company web pages of companies

Dynamic Report Generator
Our dynamic report generator lets you with ease and speed generate html reports directly in your web browser (Internet Explorer and FireFox), whether it is a single drug profile or an entire search you want have a report of.
Click here for a short video (6m12s) showing a typical drug profile

System Requirements - Operating system: Windows (2000/XP/Vista/7) and Mac OS X 10.6 (Snow Leopard) and OS X 10.7 (Lion)
- Browser Application (Internet Explorer)
- Internet access (to access related internet resources)

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Biologicals in Oncology Drug Pipeline Update.
    To find out more about Biologicals in Oncology Drug Pipeline Update, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Biologicals in Oncology Drug Pipeline Update is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Drugs' category:


Target Atlas in Liver Cancer: A Competitive Outlook
System Requirements - Operating system: Windows (2000/XP/Vista/7/8/10) and Mac OS X 10.6 (Snow Leopard) and OS X 10.7 (Lion)
- Browser Application (Internet Explorer)
- Internet access (to access related internet resources)
Learn More


TNF-Alpha Signaling Pathway in Oncology Drug Pipeline Update
BioSeeker Group have identified 534 companies plus partners who are today developing 731 TNF-alpha pathway targeting drugs in 2597 developmental projects in cancer across 286 different targets. In addition, there are 5 suspended drugs and another 313 drugs where development has been ceased. Learn More

Other selected research from the 'Drug Pipeline Updates' category:


Targeting Metabolic Pathways in Cancer Drug Pipeline Update
BioSeeker Group have identified 221 companies plus partners who are today developing 235 metabolic pathways targeting drugs in 590 developmental projects in cancer across 157 different targets. In addition, there are 2 suspended drugs and another 92 drugs where development has been ceased. Learn More


Interfering With the ECM-Receptor Interaction for the Treatment of Cancer Drug Pipeline Update
BioSeeker Group have identified 67 companies plus partners who are today developing 50 targeting ECM-receptor interaction drugs in 121 developmental projects in cancer across 52 different targets. In addition, there is 1 suspended drug and another 28 drugs where development has been ceased. Learn More

Other selected research from the 'R&D' category:


ID Signaling Pathway in Oncology Drug Pipeline Update
BioSeeker Group have identified 117 companies plus partners who are today developing 114 ID pathway targeting drugs in 493 developmental projects in cancer across 104 different targets. In addition, there is 1 suspended drug and another 62 drugs where development has been ceased. Learn More


IL-4 Signaling Pathway in Oncology Drug Pipeline Update
BioSeeker Group have identified 208 companies plus partners who are today developing 274 IL-4 pathway targeting drugs in 988 developmental projects in cancer across 161 different targets. In addition, there are 4 suspended drugs and another 105 drugs where development has been ceased. Learn More

Other selected research from the 'Oncology' category:


Oncology Drug Pathway Analyzer - Online
Get instant, interactive pathway modeling on more than 3,800 cancer drugs across more than 100 different cancer types. Learn More


The Commercial Success of Cancer Therapeutic Antibodies - The Formation of a Second Wave
The blockbuster drugs Rituxan, Avastin, and Erbitux have change the way the industry looks upon antibody treatment of cancer in the same way that Taxol changed the way pharmaceutical companies look at the possibilities in the field of cancer therapeutics. Learn More

Other selected research from the 'Biologicals' category:


Cancer Peptides: From First-in-Class to Best-in-Class?
In-depth pipeline analytics of peptide drugs in oncology showing you where the Competition is, What is first-in-class and Is First-in-Class the Best-in-Class?, Indication expansion opportunities and much more Learn More


Peptides in Oncology Drug Pipeline Update
BioSeeker Group have identified 340 companies plus partners who are today developing 356 peptide drugs in 778 developmental projects in cancer across 252 different targets. In addition, there are 4 suspended drugs and another 148 drugs where development has been ceased. Learn More